Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 96

Results For "cancer"

1026 News Found

Apollo Hospitals announces free Covid-19 vaccines to kids with co-morbidities
Hospitals | October 26, 2021

Apollo Hospitals announces free Covid-19 vaccines to kids with co-morbidities

The list of kids with co-morbidities eligible for vaccination would be announced by the government


Zydus announces update on a randomised trial of Saroglitazar Mg in NASH
Biotech | October 22, 2021

Zydus announces update on a randomised trial of Saroglitazar Mg in NASH

Incidences of Non-alcoholic Fatty Liver Disease (NAFLD) have been rising exponentially worldwide and are associated with co-morbidities including obesity, diabetes, hypertension and metabolic disorders


Global Heart Hub and Novartis partner to tackle ASCVD
Public Health | October 21, 2021

Global Heart Hub and Novartis partner to tackle ASCVD

Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease (ASCVD) care


We plan to expand into Chennai, Hyderabad and Vijayawada: Rajinish Menon, Founder & CEO, Sukino Healthcare
interviews | October 20, 2021

We plan to expand into Chennai, Hyderabad and Vijayawada: Rajinish Menon, Founder & CEO, Sukino Healthcare

Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.


FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Drug Approval | October 20, 2021

FDA approves Cyltezo, the first interchangeable biosimilar to Humira

Second interchangeable biosimilar product approved by agency


Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline
Biotech | October 18, 2021

Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline

Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme


AUM Biosciences closes US $ 27 million `Series A’ funding round
Startup | October 15, 2021

AUM Biosciences closes US $ 27 million `Series A’ funding round

Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate


IPM growth led by Covid  driven products to taper off in Q2FY22: Nirmal Bang
News | October 06, 2021

IPM growth led by Covid driven products to taper off in Q2FY22: Nirmal Bang

In Q2FY22, growth from Covid-driven products in the domestic branded formulation sales should dissipate on a QoQ basis as new covid cases have declined sharply. Vishal Manchanda, research analyst Nirmal Bang gives a preview of pharma companies in this report


Ayushman Bharat PM-JAY rates revised
Public Health | October 06, 2021

Ayushman Bharat PM-JAY rates revised

The rates for over 400 procedures were revised


Biocon launches Everolimus tablets in the US
Drug Approval | October 04, 2021

Biocon launches Everolimus tablets in the US

According to IQVIA, US sales of Everolimus (Afinitor) tablets were approximately US $ 675 million in the 12 months ending July 2021